MLN8237 (alisertib), an investigational Aurora A Kinase inhibitor, in patients with breast cancer: Emerging phase 2 results

被引：0
|
作者：
Alvarez, R. H.
DeMichele, A.
Mailliez, A.
Benaim, E.
Fingert, H.
Schusterbauer, C.
Zhang, B.
Melichar, B.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Abramson Canc Ctr, Philadelphia, PA USA
[3] Ctr Oscar Lambret, F-59020 Lille 59, France
[4] Millennium Pharmaceut Inc, Cambridge, MA USA
[5] Fak Nemocnice Olomouc, Onkol Klin, Olomouc, Czech Republic
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P6-10-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-10-02
引用
收藏
页数：2
相关论文
共 50 条
  • [21] ABSORPTION, METABOLISM, AND EXCRETION OF ALISERTIB (MLN8237), AN AURORA A KINASE INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS
    Pusalkar, Sandeepraj
    Zhou, Xiaofei
    Li, Yuexian
    Cohen, Lawrence
    Liao, Mingxiang
    Yang, Johnny
    Chong, Saeho
    Venkatakrishnan, Karthik
    Chowdhury, Swapan
    DRUG METABOLISM REVIEWS, 2015, 47 : 195 - 195
  • [22] Translational Exposure-Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)
    Huck, Jessica J.
    Zhang, Mengkun
    Mettetal, Jerome
    Chakravarty, Arijit
    Venkatakrishnan, Karthik
    Zhou, Xiaofei
    Kleinfield, Rob
    Hyer, Marc L.
    Kannan, Karuppiah
    Shinde, Vaishali
    Dorner, Andy
    Manfredi, Mark G.
    Shyu, Wen Chyi
    Ecsedy, Jeffrey A.
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (09) : 2170 - 2183
  • [23] A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.
    Olszanski, Anthony J.
    Middleton, Mark R.
    Bahleda, Rastilav
    Heist, Rebecca Suk
    Rangachari, Lakshmi
    Zhou, Xiaofei
    Bozon, Viviana
    Kneissl, Michelle
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
    Pusalkar, Sandeepraj
    Zhou, Xiaofei
    Li, Yuexian
    Cohen, Lawrence
    Yang, Jun Johnny
    Balani, Suresh K.
    Xia, Cindy
    Shyu, Wen Chyi
    Lu, Chuang
    Venkatakrishnan, Karthik
    Chowdhury, Swapan K.
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (03) : 217 - 229
  • [25] Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors
    Falchook, Gerald S.
    Venkatakrishnan, Karthik
    Sarantopoulos, John
    Kurzrock, Razelle
    Mita, Alain C.
    Fu, Siqing
    Mita, Monica M.
    Zhou, Xiaofei
    Jung, Jung Ah
    Ullmann, Claudio Dansky
    Milch, Catherine
    Rosen, Lee S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (07) : 563 - 572
  • [26] Integrated Safety Analysis of Single-Agent MLN8237 (alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies and Solid Tumors
    Benaim, Ely
    Zhou, Xiaofei
    Liu, Hua
    Leonard, E. Jane
    Freedland, Eric
    Niculescu, Liviu
    BLOOD, 2012, 120 (21)
  • [27] Open-Label, Multicenter, Phase 1 Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, With Docetaxel in Patients With Solid Tumors
    Graff, Julie N.
    Higano, Celestia S.
    Hahn, Noah M.
    Taylor, Matthew H.
    Zhang, Bin
    Zhou, Xiaofei
    Venkatakrishnan, Karthik
    Leonard, E. Jane
    Sarantopoulos, John
    CANCER, 2016, 122 (16) : 2524 - 2533
  • [28] Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    Matulonis, Ursula A.
    Sharma, Sudarshan
    Ghamande, Sharad
    Gordon, Michael S.
    Del Prete, Salvatore A.
    Ray-Coquard, Isabelle
    Kutarska, Elzbieta
    Liu, Hua
    Fingert, Howard
    Zhou, Xiaofei
    Danaee, Hadi
    Schilder, Russell J.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : 63 - 69
  • [29] Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors
    Xiaofei Zhou
    Sandeepraj Pusalkar
    Swapan K. Chowdhury
    Shawn Searle
    Yuexian Li
    Claudio Dansky Ullmann
    Karthik Venkatakrishnan
    Investigational New Drugs, 2019, 37 : 666 - 673
  • [30] Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS)
    Goldberg, Stuart L.
    Fenaux, Pierre
    Craig, Michael D.
    Gyan, Emmanuel
    Lister, John
    Kassis, Jeannine
    Pigneux, Arnaud
    Schiller, Gary J.
    Jung, JungAh
    Leonard, E. Jane
    Fingert, Howard
    Westervelt, Peter
    BLOOD, 2010, 116 (21) : 1341 - 1341
12345